Kneu Health turns everyday smartphone interactions—voice, movement and memory tests—into clinically validated biomarkers that help clinicians detect neurological decline earlier and guide personalized interventions. Built on one of the world’s largest Parkinson’s and dementia datasets, the platform has collected more than 500,000 digital measures from 1,400+ users across NHS and U.S. deployments. Its FDA-cleared tremor measurement tool allows continuous, remote monitoring without additional hardware, embedding longitudinal data directly into clinical workflows. Reported outcomes include 67% faster-than-standard access to treatment, medication adjustments in over half of monitored patients, and up to 30% improvements in patient knowledge, confidence and self-management. NHS pilots cite a 30% boost in efficiency, reductions in emergency admissions and the equivalent of 1,000 hospital bed days saved. With contracts already underway at Cedars-Sinai and Mass General Brigham, Kneu plans to use new capital to scale U.S. Parkinson’s deployments, expand commercial capacity and advance its dementia monitoring capabilities. The latest financing brings its total funding to $11.2 million, supporting the company’s goal of making continuous neurological care core infrastructure for health systems.

Total raised

$8M

Funding rounds

2

Latest round

Seed

Latest activity

Oct 2025